CD146 increases stemness and aggressiveness in glioblastoma and activates YAP signaling
Open Access
- 5 July 2022
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 79 (8) , 1-19
Abstract
Glioblastoma (GBM), a highly malignant and lethal brain tumor, is characterized by diffuse invasion into the brain and chemo-radiotherapy resistance resulting in poor prognosis. In this study, we examined the involvement of the cell adhesion molecule CD146/MCAM in regulating GBM aggressiveness. Analyses of GBM transcript expression databases revealed correlations of elevated CD146 levels with higher glioma grades, IDH-wildtype and unmethylated MGMT phenotypes, poor response to chemo-radiotherapy and worse overall survival. In a panel of GBM stem cells (GSCs) variable expression levels of CD146 were detected, which strongly increased upon adherent growth. CD146 was linked with mesenchymal transition since expression increased in TGF-ß-treated U-87MG cells. Ectopic overexpression of CD146/GFP in GG16 cells enhanced the mesenchymal phenotype and resulted in increased cell invasion. Conversely, GSC23-CD146 knockouts had decreased mesenchymal marker expression and reduced cell invasion in transwell and GBM-cortical assembloid assays. Moreover, using GSC23 xenografted zebrafish, we found that CD146 depletion resulted in more compact delineated tumor formation and reduced tumor cell dissemination. Stem cell marker expression and neurosphere formation assays showed that CD146 increased the stem cell potential of GSCs. Furthermore, CD146 mediated radioresistance by stimulating cell survival signaling through suppression of p53 expression and activation of NF-κB. Interestingly, CD146 was also identified as an inducer of the oncogenic Yes-associated protein (YAP). In conclusion, CD146 carries out various pro-tumorigenic roles in GBM involving its cell surface receptor function, which include the stimulation of mesenchymal and invasive properties, stemness, and radiotherapy resistance, thus providing an interesting target for therapy.Keywords
Funding Information
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (016.Vidi.171016)
This publication has 47 references indexed in Scilit:
- The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domainProceedings of the National Academy of Sciences, 2012
- Laminin-411 Is a Vascular Ligand for MCAM and Facilitates TH17 Cell Entry into the CNSPLOS ONE, 2012
- CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancerProceedings of the National Academy of Sciences, 2011
- The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewalNature Cell Biology, 2011
- The Hippo–YAP pathway in organ size control and tumorigenesis: an updated versionGenes & Development, 2010
- Isolation and characterization of CD146+ multipotent mesenchymal stromal cellsExperimental Hematology, 2008
- Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth controlGenes & Development, 2007
- A Perivascular Niche for Brain Tumor Stem CellsCancer Cell, 2007
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- Purification and characterization of an 82-kD membrane protein as a neurite outgrowth factor binding protein: possible involvement of NOF binding protein in axonal outgrowth in developing retina.Journal of Cell Biology, 1991